The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients
NCT ID: NCT00001082
Last Updated: 2013-10-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
505 participants
INTERVENTIONAL
1996-12-31
1999-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The optimal treatment for HIV infection and the prevention of CMV disease has not been identified. Currently available antiretroviral therapies are hampered by both significant toxicities and the development of resistance. In addition, agents for preventing CMV disease, such as oral ganciclovir, are complicated by poor bioavailability and decreased compliance secondary to toxicities. Moreover, discordant results have been reported regarding the effectiveness of oral ganciclovir for preventing CMV disease. There is a need for newer agents with anti-HIV and anti-herpesvirus activity that have good pharmacokinetic and safety profiles and that will be well tolerated by patients. Adefovir dipivoxil is an oral pro-drug of PMEA, a nucleoside analog with activity against a broad spectrum of retroviruses and herpesviruses, including important human pathogens, such as HIV-1, HIV-2 and CMV. Due to its anti-HIV and anti-herpesvirus activity, adefovir dipivoxil may be able to decrease the incidence of opportunistic herpesvirus infections and prolong survival in patients with advanced HIV infection.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All patients will be enrolled within the first 18 months of the study. They will be randomized to 1 of 2 groups. Group 1 will be comprised of 1080 patients and will receive adefovir dipivoxil plus L-carnitine and group 2 will be comprised of 1080 patients and will receive a placebo plus L-carnitine. At least the first 400 patients enrolled (200 in each group) will comprise the safety-HIV virology cohort. These patients will have more frequent follow up visits, additional laboratory evaluations, and more intensive safety data information during the first 6 months. NOTE: At least 850 patients who are infected with CMV are followed for the development of CMV end-organ disease in a CMV prophylaxis substudy.
AS PER AMENDMENT 8/7/97: All patients are enrolled in the primary study and randomized to the treatment or placebo regimen. Within the primary study, patients meeting specified criteria may be enrolled in one or more of the following cohorts:
1. Safety-HIV virology cohort (at least the first 400 patients enrolled in the study regardless of CMV status).
2. CMV bDNA cohort (those patients in the safety-HIV virology cohort who are CMV-positive).
3. CMV-virology cohort (the first 400 patients in the CMV bDNA cohort enrolled at sites able to obtain CMV urine cultures).
All patients who are CMV-positive are enrolled in the CMV prophylaxis substudy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Participants will receive adefovir dipivoxil and L-carnitine
Levocarnitine
500 mg tablet taken orally daily
Adefovir dipivoxil
120 mg tablet taken orally daily
2
Participants will receive adefovir dipivoxil placebo and L-carnitine.
Levocarnitine
500 mg tablet taken orally daily
Adefovir dipivoxil placebo
Oral placebo tablet taken daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Levocarnitine
500 mg tablet taken orally daily
Adefovir dipivoxil
120 mg tablet taken orally daily
Adefovir dipivoxil placebo
Oral placebo tablet taken daily
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Allowed:
* Chronically administered concomitant therapies for HIV and opportunistic diseases, including chemotherapy for cutaneous Kaposi's sarcoma, must be on these therapies for at least 30 days prior to study entry.
* Short courses of oral antibiotics or other therapies given for a limited period of 3 weeks.
* Episodic use of IV acyclovir or oral acyclovir \> 1g/day for treatment of acute illness is permitted at the clinician's discretion.
Patients must have:
* A working diagnosis of HIV infection based on the patient's medical history, behavioral history, clinical signs and symptoms, or results of other laboratory tests.
* CD4+ cell count \<= 100 cells/mm3 within 60 days prior to randomization (OR, AS PER AMENDMENT 8/7/97, a CD4+ cell count that is both \> 100 and \<= 200 cells/mm3 within 60 days prior to randomization and a documented nadir CD4+ cell count \<= 50 cells/ mm3 at any time prior to randomization).
* Reasonably good health.
* Life expectancy of at least 6 months.
* Access to a refrigerator for the storage of adefovir dipivoxil.
* Signed informed consent from parent or legal guardian for patients less than 18 years of age.
AS PER AMENDMENT 8/7/97:
* CMV serology (IgG) positive (CMV bDNA cohort and CMV-virology cohort).
Exclusion Criteria
Patients with the following symptoms and conditions are excluded:
* Evidence of active CMV disease at screening.
* Conditions that would require use of medications listed in Exclusion Concurrent Medications.
Concurrent Medication:
Excluded:
* Any investigational anti-CMV agent.
* Adenine arabinoside (vidarabine).
* Amantadine hydrochloride (Symmetrel).
* Cidofovir (Vistide).
* CMV hyperimmune globulin.
* Cytosine arabinoside (cytarabine).
* Famciclovir.
* Foscarnet (phosphonoformic acid).
* Ganciclovir (Cytovene).
* GW 1263W94 (Benzamidazole).
* Idoxuridine.
* Intravenous acyclovir.
* ISIS 2922 (Anti-sense).
* Lobucavir.
* MSL109.
* Oral acyclovir \> 1 g/day.
* Valacyclovir.
Patients with the following prior conditions are excluded:
* History of CMV end-organ disease.
Prior Medication:
Excluded within 2 weeks of randomization:
* Any investigational anti-CMV agent.
* Adenine arabinoside (vidarabine).
* Amantadine hydrochloride (Symmetrel).
* Cidofovir (Vistide).
* CMV hyperimmune globulin.
* Cytosine arabinoside (cytarabine).
* Famciclovir.
* Ganciclovir (Cytovene).
* GW 1263W94 (Benzamidazole).
* Idoxuridine.
* Intravenous acyclovir.
* ISIS 2922 (Anti-sense).
* Lobucavir.
* MSL109.
* Oral acyclovir \> 1 g/day.
* Valacyclovir.
Excluded within 60 days prior to study entry:
* Foscarnet.
13 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brosgart C
Role: STUDY_CHAIR
Fisher E
Role: STUDY_CHAIR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Community Consortium / UCSF
San Francisco, California, United States
Denver CPCRA / Denver Public Hlth
Denver, Colorado, United States
Washington Reg AIDS Prog / Dept of Infect Dis
Washington D.C., District of Columbia, United States
AIDS Research Consortium of Atlanta
Atlanta, Georgia, United States
AIDS Research Alliance - Chicago
Chicago, Illinois, United States
Louisiana Comm AIDS Rsch Prog / Tulane Univ Med
New Orleans, Louisiana, United States
Wayne State Univ - WSU/DMC / Univ Hlth Ctr
Detroit, Michigan, United States
Henry Ford Hosp
Detroit, Michigan, United States
Southern New Jersey AIDS Cln Trials / Dept of Med
Camden, New Jersey, United States
North Jersey Community Research Initiative
Newark, New Jersey, United States
Partners in Research / New Mexico
Albuquerque, New Mexico, United States
Harlem AIDS Treatment Grp / Harlem Hosp Ctr
New York, New York, United States
The Research and Education Group
Portland, Oregon, United States
Philadelphia FIGHT
Philadelphia, Pennsylvania, United States
Richmond AIDS Consortium / Div of Infect Diseases
Richmond, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Fisher E, Brosgart C, Cohn D, Chaloner K, Pulling C, Alston B, Schmetter B, El-Sadr W. Placebo (PLC)-controlled, multicenter trial of adefovir dipivoxil (ADV) in patients (pt) with HIV disease. Conf Retroviruses Opportunistic Infect. 1999 Jan 31-Feb 4;6th:160 (abstract no 491)
Brosgart C, Fisher E, Pulling C, Chaloner K, Cohn D, Elsadr W, Verheggen R, Schmetter B, Alston B. Prevalence of asymptomatic CMV retinitis (CMVR) in AIDS patients. Conf Retroviruses Opportunistic Infect. 1999 Jan 31-Feb 4;6th:152 (abstract no 453)
Fisher E, Brosgart C, Cohn D, Chaloner K, Pulling C, Schmetter B, Alston B, El-Sadr W. Safety of adefovir dipivoxil (ADV) and incidence of proximal renal tubular disorder (PRTD) in a placebo (PLC)-controlled trial in patients (pt) with advanced HIV disease. Conf Retroviruses Opportunistic Infect. 1999 Jan 31-Feb 4;6th:195 (abstract no 678)
Brosgart C, Pulling C, Chaloner K, Fisher E, Coakley D, Diggins M, Ivannidis J. Serum carnitine levels in AIDS patients with advanced HIV disease from the CPCRA 039 trial. Int Conf AIDS. 1998;12:1094 (abstract no 60508)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11589
Identifier Type: REGISTRY
Identifier Source: secondary_id
CPCRA 039
Identifier Type: -
Identifier Source: org_study_id